Skip to Content
Upcoming Webinar

A Combination Treatment for Patients with Advanced Renal Cell Carcinoma

Date: September 18, 2025 | 2:00 PM
When: Thursday, September 18 | 2 p.m. EST

The 5-year CHECKMATE-9ER follow-up offers the most extensive data to date on CABOMETYX + OPDIVO in first-line advanced renal cell carcinoma — including long-term survival outcomes, safety signals, and quality-of-life measures across diverse patient groups.

In this session, Jennifer Hasiak, PharmD from Hematology & Oncology Consultants will:

  • Review efficacy and safety data from the primary analysis and extended follow-up
  • Examine exploratory findings on quality of life and sites of metastasis
  • Outline dosing strategies and management of treatment-related adverse events
  • Translate trial evidence into practical guidance for clinical practice

Gain the insight you need to make evidence-based decisions and optimize care for patients with aRCC.

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.